Under a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it releases its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to this class of drugs.
Per forecasts, over two billion will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the jabs that can aid individuals in losing considerable weight, says the organization.
Weight-Loss Drug Supply Crisis
Even in the present most favorable case, the production of GLP-1 therapies could only cover around 100 million people – under 10% of those who need them, according to the WHO.
The recommendation calls on governments and firms to widen availability, by measures such as patent sharing.
A patent on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so people eat less.
Patients commonly see weight reduction in the initial weeks of beginning the once-weekly jabs.
Evidence points to patients may put most of the weight back on after a year of halting the drug, because their usual appetite return.
Being overweight or obese increases your chance for contracting health problems, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, according to the health agency.
